|
Torrex Chiesi Pharma - Austria and Eastern
Europe
Torrex Chiesi, even with a small number of launches, managed to achieve a significant sales growth of 25% (including sales to licensees and distributors), mainly on the excellent sales of PBCD (Flamexin®) in the Central and Eastern European Countries.
A cooperation on the product Ferriprox® (deferiprone) was concluded with the Canadian Apotex for some countries. In Austria, Formoterol was successfully launched in copromotion with Novartis, starting at the end of the year.
The market share of Curosurf® in the CEE countries already reached 75% to 100%. Business in Romania developed positively and the takeover of Flamexin® sachets from Fournier was very successful. Hungary suffered some price erosion on prescription products due to new generics. In the Czech Republic, budesonide was launched in April 2006 and successfully developed. The major objectives for 2007 are to prepare for launches of Chiesi new respiratory products. |
